NCT04166006View on ClinicalTrials.gov

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

April 30, 2027

Study Completion Date

December 31, 2031

Conditions
Head Neck TumorsNeuroendocrine TumorsSoft Tissue SarcomaRare CancerVaccination
Interventions
BIOLOGICAL

Autologous DC vaccine

7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)

DRUG

Interleukin-2

Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).

Trial Locations (1)

47014

RECRUITING

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER